Dr. Thomas Sycha, Universitätsprofessor, Facharzt für Neurologie

Wissenschaftliche Arbeiten


  1. Vossen MG, Gattringer KB, Wenisch J, Khalifeh N, Koreny M, Spertini V, Allerberger F, Graninger W, Kornschober C, Lagler H, Reitner A, Sycha T, Thalhammer F. The First Case(s) of Botulism in Vienna in 21 Years: A Case Report. Case Rep Infect Dis. 2012;2012:438989. Epub 2012 Jun 21.

  2. Seidel S, Kasprian G, Furtner J, Schöpf V, Essmeister M, Sycha T, Auff E, Prayer D. Mirror therapy in lower limb amputees–a look beyond primary motor cortex reorganization. Rofo. 2011 Nov; 183(11):1051-7. Epub 2011 Sep 28.

  3. Kranz G, Paul A, Voller B, Posch M, Windischberger C, Auff E, Sycha T.Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study. Br J Dermatol. 2011;164(1):176-81.

  4. Seidel S, Kasprian G, Prayer D, Krssák M, Sycha T, Auff E. Visualisation of treatment response in a case of cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry. 2010 (Epub ahead of print)

  5. Seidel S, Kechvar-Parast J, Sycha T, Zeitlhofer J. The first case of a ‘jumping stump’ syndrome in a lower limb amputee responding to pramipexole. Eur J Neurol. 2010 (Epub ahead of print)

  6. Paul A, Kranz G, Schindl A, Kranz GS, Auff E, Sycha T. Diode laser hair removal does not interfere with botulinum toxin A treatment against axillary hyperhidrosis. Lasers Surg Med. 2010;42(3):211-4.

  7. Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. J Pain Symptom Manage. 2010;39(4):768-78.

  8. Findl O, Buehl W, Bauer P, Sycha T. Interventions for preventing posterior capsule opacification. Cochrane Database Syst Rev. 2010 Feb 17;2:CD003738.

  9. Seidel S, Kasprian G, Sycha T, Auff E. Mirror therapy for phantom limb pain–a systematic review. Wien Klin Wochenschr. 2009;121(13-14):440-4.

  10. Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin. 2009;25:1573-84.

  11. Kranz G, Haubenberger D, Voller B, Posch M, Schnider P, Auff E, Sycha T. Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov Disord. 2009;24(2):231-6.

  12. Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. Cochrane Database Syst Rev. 2008;(4):CD004844.

  13. Draxler J, Schuch M, Paul A, Sycha T, Valenta C, Likar R, Gustorff B. (Topical application of morphine and buprenorphine gel has no effect in the sunburn model). Schmerz. 2008;22(5):571-4. http://www.ncbi.nlm.nih.gov/pubmed/18438689

  14. Kranz G, Sycha T, Voller B, Kranz GS, Schnider P, Auff E. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008; 70(2):133-6. http://www.ncbi.nlm.nih.gov/pubmed/18180443

  15. Leitner C, Mair P, Paul B, Wick F, Mittermaier C, Sycha T, Ebenbichler G. Reliability of posturographic measurements in the assessment of impaired sensorimotor function in chronic low back pain. J Electromyogr Kinesiol. 2009;19(3):380-90.

  16. Vass C, Hirn C, Sycha T, Findl O, Bauer P, Schmetterer L. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2007;(4):CD003167.

  17. Kotzailias N, Elwischger K, Sycha T, Rinner W, Quehenberger P, Auff E, Müller C. Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients. J Stroke Cerebrovasc Dis. 2007;16(5):199-202.

  18. Sycha T, Samal D, Chizh B, Lehr S, Gustorff B, Schnider P, Auff E. Lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg. 2006;102:509-16.

  19. Sycha T, Kotzailias N, Kranz G, Trautinger F, Schnider P, Auff E. UV-B Irradiation Attenuates Dermal Effects of Botulinum Toxin A: A Randomized, Double-Blind, Placebo-Controlled Study. Dermatol Surg. 2007;33 Suppl 1:S92-6.

  20. Kranz G, Sycha T, Voller B, Gleiss A, Schnider P, Auff E. Pain sensation during intradermal injections of three different botulinum toxin preparations in different doses and dilutions. Dermatol Surg. 2006;32:886-90.

  21. Tribl GG, Sycha T, Kotzailias N, Zeitlhofer J, Auff E. Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatry. 2005;76:181-5.

  22. Ossege M, Sycha T, Aigner M, Schmetterer L, Eichler HG, Muller M, Konig F, Bauer P. Effect of information on reported adverse events in a placebo-controlled trial. Drug Saf. 2005;28:81-7.

  23. Sycha T, Anzenhofer S, Lehr S, Schmetterer L, Chizh B, Eichler HG, Gustorff B Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain model. Pain 2005;113:316-322

  24. Tribl GG, Waldhauser F, Druml W, Sycha T, Endler G, Zeitlhofer J, Auff E. Loss of normal circadian profile of urine excretion in idiopathic restless legs syndrome. Sleep Med. 2005 Sep;6(5):391-8. http://www.ncbi.nlm.nih.gov/pubmed?term=16099717

  25. Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud’s phenomenon: a pilot study. Eur J Clin Invest. 2004;34:312-3.

  26. Sycha T, Kranz G, Auff E, Schnider P. Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature. J Neurol. 2004;251 Suppl 1:I19-30.

  27. Gustorff B, Hoechtl K, Sycha T, Felouzis E, Lehr S, Kress HG. The effects of remifentanil and gabapentin on hyperalgesia in a new extended inflammatory skin pain model in healthy volunteers. Anesth Analg. 2004;98:401-7

  28. Gustorff B, Anzenhofer S, Sycha T, Lehr S, Kress HG. The sunburn pain model: the stability of primary and secondary hyperalgesia over 10 hours in a crossover setting. Anesth Analg. 2004;98:173-7

  29. Tribl GG, Waldhauser F, Sycha T, Auff E, Zeitlhofer J. Urinary 6-hydroxy-melatonin-sulfate excretion and circadian rhythm in patients with restless legs syndrome. J Pineal Res. 2003;35:295-6.

  30. Sycha T, Vass C, Findl O, Bauer P, Groke I, Schmetterer L, Eichler H. Interventions for normal tension glaucoma. The Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD002222. DOI: 10.1002/14651858.CD002222.

  31. Voller B, Sycha T, Gustorff B, Schmetterer L, Lehr S, Eichler HG, Auff E, Schnider P. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology. 2003;61:940-4.

  32. Sycha T, Gustorff B, Lehr S, Tanew A, Eichler HG, Schmetterer L. A simple pain model for the evaluation of analgesic effects of NSAIDs in healthy subjects. Br J Clin Pharmacol. 2003;56:165-72.

  33. Homoncik M, Malec M, Marsik C, Sycha T, Anzenhofer S, Gustorff B, Jilma B. Rofecoxib exerts no effect on platelet plug formation in healthy volunteers.Clin Exp Rheumatol. 2003;21(2):229-31.

  34. Windischberger C, Langenberger H, Sycha T, Tschernko EM, Fuchsjager-Mayerl G, Schmetterer L, Moser E. On the origin of respiratory artifacts in BOLD-EPI of the human brain. Magn Reson Imaging. 2002;20:575-82.

  35. Jonas S., Wild C., Frank W., Schmetterer L., Sycha T. Immunglobuline in der Transplantationsmedizin: Prävention und Therapie von Cytomegalievirus-Infektionen - ein Assessment. Transplantationsmedizin 2002; 2:65-73

Diese Website verwendet Cookies. Wenn Sie diese Website nutzen, ohne die Cookie-Einstellungen Ihres Browsers zu ändern oder hier einen Opt-Out-Cookie zu setzen, stimmen Sie der Verwendung von Cookies zu. Nähere Informationen zum Datenschutz.×